Kura Oncology Stock News

Equities analysts expect that Kura Oncology, Inc. (NASDAQ:KURA) will announce ($0.54) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Kura Oncologys earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.62). Kura Oncology posted earnings per share of ($0.45) in the same []

SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences:

SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

Credit Suisse AG boosted its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 37.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,727 shares of the companys stock after acquiring an additional 15,625 shares during the quarter. Credit Suisse AG owned []

Credit Suisse AG boosted its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 37.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,727 shares of the companys stock after buying an additional 15,625 shares during the period. Credit Suisse AG []

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2021 Results - Earnings Call Transcript

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

– Combination of tipifarnib and alpelisib shows robust activity in preclinical PDX models of HRAS and PIK3CA pathway dependent tumors –

SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment